Status:
UNKNOWN
Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia
Lead Sponsor:
China Medical University Hospital
Conditions:
Bronchopulmonary Dysplasia
Extremely Premature Infants
Eligibility:
All Genders
1-6 years
Phase:
PHASE1
Brief Summary
Mesenchymal stem cells (MSCs) have been reported to be effective to prevent alveolar growth arrest in experimental bronchopulmonary dysplasia (BPD). The aim is to treat the extremely premature infant ...
Eligibility Criteria
Inclusion
- severe BPD, defined by the National Institute of Child Health and Human Development workshop, who conventional therapies (including furosemide and theophylline, and HFO ventilation) has failed
Exclusion
- severe congenital anomalies
- severe intraventricular hemorrhage ≥ grade 3 or cystic periventricular leukomalacia.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2012
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01207869
Start Date
July 1 2010
End Date
July 1 2012
Last Update
September 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan, 404